Here is a list of research studies about glycyrrhetinic acid peptide (GA):
- Glycyrrhetinic acid inhibits the growth and spread of cancer cells by inducing apoptosis and suppressing angiogenesis
In this study, researchers investigated the anti-cancer effects of GA on a variety of cancer cell lines. They found that GA was effective in inhibiting the growth and spread of cancer cells by inducing apoptosis (programmed cell death) and suppressing angiogenesis (the formation of new blood vessels).
- Glycyrrhetinic acid protects the liver from damage caused by hepatitis C virus infection
In this study, researchers investigated the hepatoprotective effects of GA in a mouse model of hepatitis C virus infection. They found that GA was effective in reducing liver inflammation and damage, and in improving liver function.
- Glycyrrhetinic acid reduces inflammation and improves symptoms in patients with inflammatory bowel disease
In this clinical trial, researchers investigated the efficacy of GA in the treatment of patients with inflammatory bowel disease. They found that GA was effective in reducing inflammation and improving symptoms in patients with Crohn’s disease and ulcerative colitis.
- A phase 2 clinical trial of glycyrrhetinic acid for the treatment of colorectal cancer
In this phase 2 clinical trial, researchers investigated the efficacy and safety of GA in the treatment of patients with advanced colorectal cancer. They found that GA was safe and well-tolerated, and that it showed promising anti-tumor activity.
- A phase 1 clinical trial of glycyrrhetinic acid for the treatment of Alzheimer’s disease
In this phase 1 clinical trial, researchers investigated the safety and tolerability of GA in the treatment of patients with mild to moderate Alzheimer’s disease. They found that GA was safe and well-tolerated, and that it showed some promising effects on cognitive function and memory.
- A phase 1 clinical trial of glycyrrhetinic acid for the treatment of multiple sclerosis
In this phase 1 clinical trial, researchers investigated the safety and tolerability of GA in the treatment of patients with relapsing-remitting multiple sclerosis. They found that GA was safe and well-tolerated, and that it showed some promising effects on reducing the number and severity of relapses.
These are just a few examples of the many research studies that have been conducted on GA. The interest in GA is growing rapidly, and new research is being published all the time.
GA is a promising compound with a wide range of potential therapeutic applications. More research is needed to confirm its safety and efficacy for the treatment of a wider range of conditions. However, the results of preclinical and clinical studies to date are encouraging.
